SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir's recent report and forward guidance are sparking heated debate, with some celebrating the company's growth in the AI space while others express concerns about its high valuation. The community is divided between those who see long-term potential and those who anticipate a correction. Discussions also involve CEO Karp's commentary and Michael Burry's short position against the stock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid community discussion around a failed confirmatory trial for its PMO therapies, overshadowing otherwise positive earnings reports. Investors are weighing the implications of the trial results on future revenue, particularly in light of Elevidys sales and potential impacts on payer coverage.  Debate centers on whether the market reaction is an overcorrection and if long-term prospects remain strong due to potential buyouts or positive developments in the pipeline.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid mixed sentiment following earnings, with community discussions focusing on revenue beats versus EPS miss and potential risks related to debt and dilution. While some traders are securing profits, others see the dip as a buying opportunity, especially with ongoing developments in nuclear energy and rare earth elements. The stock's movement is also influenced by broader geopolitical factors affecting the rare earth sector.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amid discussions around Q3 earnings, potential short squeeze, and a possible partnership with Novo Nordisk. Community talking points revolve around the company's growth potential, expansion into new markets like comprehensive testing and international, and revenue acceleration, with some expressing concerns around profitability and volatility. Speculation around partnerships and target prices is also contributing to the heightened interest.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid discussions about its strategic direction and upcoming R2 vehicle launch. The community is focused on the company's potential to compete in the mass market and address existing quality and service concerns. Some are also considering how recent partnerships and fleet orders might impact the company's growth.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab Holdings is trending amid discussions about its earnings potential and recent option activity, with call buying suggesting bullish sentiment. Community members are debating the reasons behind the stock's recent movements, the impact of raised guidance, and whether it represents a long-term growth opportunity in the Southeast Asian market. There is also discussion around a settlement for investors and potential inclusion in the S&P 500.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors discuss a potential offering following recent earnings and a new clinical program, while also considering the impact of a new CFO. The community debates management's spending and strategy, as well as the lawsuit against CMS, with some expressing frustration over the stock's performance despite company progress. Bullish investors focus on revenue growth, potential acquisitions, and positive analyst ratings, while bears cite concerns about dilution and management decisions.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to investor reactions to Michael Burry's reported call options and the company's ongoing legal battles with Novo Nordisk over the acquisition of Metsera. Community discussions revolve around the potential outcomes of these lawsuits and their implications for Pfizer's position in the competitive obesity therapeutics market, as well as speculation regarding potential acquisitions like Viking Therapeutics.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to concerns around increased AI spending and uncertain monetization, sparking worry about future profitability. The community is debating whether the stock is oversold, with some anticipating a potential rebound, while others fear further declines and draw comparisons to past market corrections. Despite solid ad revenue recovery and a strong position in the AI/VR space, META struggles to maintain the explosive momentum of its peers, leading some to view it as a potential value play amidst broader tech sector strength.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending as investors digest recent earnings and future guidance, with community debates focusing on the company's pivot towards AI data centers and its partnership with NVIDIA. Concerns are emerging around revenue forecasts, potential market share losses to competitors, and a possible delay in seeing returns from the AI sector until 2027. Despite differing opinions on short-term performance, long-term investors express confidence in NVTS's potential within the growing AI and power semiconductor market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of +190.32% and +59.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics Reports Third Quarter 2025 Financial Results

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update. We delivered outstanding commercial performance in the third...

Travere Therapeutics to Report Third Quarter 2025 Financial Results

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company...

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney...

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

What Makes Travere (TVTX) a New Strong Buy Stock

Travere (TVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?

MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of...

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TVTX News

TVTXTravere Therapeutics Inc